Angelman Syndrome - 10 Studies Found Completed : Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances : Sleep Problems : 2013-07-16 : Drug: Circadin 2 mg First arm Completed : Genomic Imprinting and Assisted Reproductive Technologies : Natural Pregnancy Pregnancy, Ovarian : 2008-10-15 Withdrawn : An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder : Autism Spectrum Disorder : 2014-08-21 : Drug: EPI-743 Other Name: Vincerinone TM Active, not recruiting : Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities : Sleep Disorders : 2013-07-11 : Drug: Circadin 2/5/10 mg Activ COMPLETED : Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome : Angelman Syndrome : 2026-01-07 : The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device.In this study, the testing involved with t Completed : Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. : Angelman Syndrome : 2026-01-07 : Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.I COMPLETED : An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome : Angelman Syndrome : 2026-01-07 : NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks. COMPLETED : A Study of the Safety and Tolerability of GTX-102 in Children with Angelman Syndrome : Angelman Syndrome : 2026-01-07 : antisense oligonucleotide COMPLETED : A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) : Angelman Syndrome : 2026-01-07 : In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 week COMPLETED : A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. : Angelman Syndrome : 2026-01-07 : Alogabat will be administered QD with dose depending on cohort and age of the participant.
